scholarly journals PCN46 COST SAVINGS RELATED TO SUPERIOR ADVERSE EVENT PROFILE OF BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE IN THE FIRST-LINE THERAPY OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY: A SENSITIVITY ANALYSIS ON THE ECOG STATUS

2009 ◽  
Vol 12 (7) ◽  
pp. A265 ◽  
Author(s):  
D Heigener ◽  
HG Bischoff ◽  
K Banz ◽  
S Walzer
Keyword(s):  
Lung Cancer ◽  
Sensitivity Analysis ◽  
Adverse Event ◽  
Cost Savings ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
Adverse Event Profile ◽  
First Line Therapy ◽  
Line Therapy

scholarly journals Cytotoxic Chemotherapy as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer in Taiwan: Daily Practice

2016 ◽  
Vol 7 (11) ◽  
pp. 1515-1523 ◽  
Author(s):  
Yi-Hsin Liang ◽  
Yu-Yun Shao ◽  
Bin-Chi Liao ◽  
Ho-Sheng Lee ◽  
James Chih-Hsin Yang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Daily Practice ◽  
Cytotoxic Chemotherapy ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

scholarly journals Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study

Lung Cancer ◽  
2018 ◽  
Vol 125 ◽  
pp. 273-281 ◽  
Author(s):  
Shirish M. Gadgeel ◽  
James P. Stevenson ◽  
Corey J. Langer ◽  
Leena Gandhi ◽  
Hossein Borghaei ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Phase 1 ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy ◽  
Platinum Based Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document